Form 4: Sonoma Pharmaceuticals: CFO Receives Stock Units

Jerome J. Dvonch, Chief Financial Officer of Sonoma Pharmaceuticals, Inc., was granted 10,000 Restricted Stock Units (RSUs) on July 9, 2026.

Summary

• Jerome J. Dvonch, the Chief Financial Officer of Sonoma Pharmaceuticals, Inc., received a grant of 10,000 Restricted Stock Units (RSUs).
• These RSUs represent a contingent right to receive one share of common stock per unit.
• The RSUs are scheduled to vest on the third anniversary of the grant date or upon a change of control of the company.
• The grant was awarded to Mr. Dvonch for services performed.
• Following this transaction, Mr. Dvonch beneficially owns 44,391 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard executive compensation event (RSU grant) without immediate financial performance indicators or significant strategic shifts.

Positives

• Grant of 10,000 RSUs to the CFO, indicating continued incentive and retention efforts.
• The RSUs are tied to service performed, aligning executive compensation with company contributions.
• Mr. Dvonch's beneficial ownership increases to 44,391 shares, demonstrating a vested interest in the company's success.

Risks

• The value of the RSUs is contingent on the company's future performance and stock price.
• Vesting is subject to a change of control, which may not occur.
• The RSUs are subject to forfeiture if certain conditions are not met.

Future Outlook

The RSUs vest on the third anniversary of the grant date or upon a change of control, indicating a forward-looking incentive tied to long-term company value and potential strategic events.

Management Comments

• "Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock."
• "The RSUs vest on the third anniversary of the grant date, or upon change of control."
• "The RSUs were awarded and granted to Mr. Dvonch for services performed."

Industry Context

StockSavvy.ai notes that grants of Restricted Stock Units (RSUs) are a common form of executive compensation in the pharmaceutical and biotechnology sectors, used to attract, retain, and incentivize key management personnel by aligning their interests with shareholders through long-term equity awards.

Stakeholder Impact

• Shareholders: The grant of RSUs to the CFO aligns executive interests with long-term shareholder value, but the immediate impact on share price is negligible. Increased beneficial ownership by management can be seen as a positive signal.
• Employees: This filing does not directly impact other employees, but it reflects standard executive compensation practices within the company.
• Management: The CFO receives an incentive tied to service and potential future events, reinforcing their commitment to the company.

Next Steps

• Vesting of 10,000 RSUs on the third anniversary of the grant date (July 9, 2029) or upon a change of control.

Key Dates

Keywords

Sonoma Pharmaceuticals, SNOA, Form 4, SEC Filing, Restricted Stock Units, RSUs, Executive Compensation, Jerome J. Dvonch, Chief Financial Officer, Beneficial Ownership